(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 January 2010 (21.01.2010)

PCT

(10) International Publication Number
WO 2010/007082 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 37/06* (2006.01)
A61K 39/395 (2006.01) *A61P 19/02* (2006.01)

(21) International Application Number:
PCT/EP2009/059030

(22) International Filing Date:
15 July 2009 (15.07.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08160671.7 17 July 2008 (17.07.2008) EP
09160326.6 15 May 2009 (15.05.2009) EP

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **HEUSSER, Christoph** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **NEUGEBAUER, Julia** [DE/DE]; Steinhauser Strasse 25B, 81677 München (DE). **SCHAADT, Eveline** [DE/DE]; Kolumbusstrasse 22, 81543 München (DE). **URLINGER, Stefanie** [DE/DE]; Asternstrasse 12, 80689 München (DE). **WOISETSCHLAEGER, Maximilian** [AT/AT]; Balthasar-Krauss-Gasse 44/3, A-2380 Perchtoldsdorf (AT).

(74) Agent: **BOURGAREL, Denis**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2010/007082 A1

(54) **Title**: COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES

(57) **Abstract**: Antibodies that specifically bind to the BAFF receptor (BAFFR). More specifically antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.